Barclays PLC Purchases 56,244 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Barclays PLC lifted its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 433.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,222 shares of the company’s stock after purchasing an additional 56,244 shares during the period. Barclays PLC owned 0.15% of Y-mAbs Therapeutics worth $910,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. State Street Corp increased its stake in shares of Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after purchasing an additional 405,169 shares during the period. Caligan Partners LP increased its stake in Y-mAbs Therapeutics by 105.3% during the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after acquiring an additional 613,175 shares during the period. Dimensional Fund Advisors LP increased its stake in Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after acquiring an additional 65,732 shares during the period. Millennium Management LLC increased its stake in Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after acquiring an additional 67,233 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Y-mAbs Therapeutics by 9.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 279,577 shares of the company’s stock worth $3,676,000 after acquiring an additional 23,982 shares during the period. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB stock opened at $7.76 on Tuesday. The stock’s fifty day moving average price is $11.72 and its two-hundred day moving average price is $12.43. The company has a market cap of $347.56 million, a PE ratio of -14.37 and a beta of 0.61. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $6.48 and a fifty-two week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. During the same period last year, the business earned ($0.18) EPS. On average, equities analysts predict that Y-mAbs Therapeutics, Inc. will post -0.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on YMAB. Oppenheimer began coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an “outperform” rating and a $23.00 price objective on the stock. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. HC Wainwright restated a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Finally, Wedbush restated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $20.89.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.